Fewer Cancer Diagnoses During COVID-19 Outbreak in the Netherlands
Multifactorial reasons involving patients, general practitioners and the healthcare system
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Multifactorial reasons involving patients, general practitioners and the healthcare system
FDA also approved the Myriad myChoice® CDx as a companion diagnostic for olaparib
Efficacy was evaluated in a multicentre, open-label, multi-cohort LIBRETTO-001 trial
Antibodies more often undetectable in patients who received anticancer treatment in the month prior to testing
Application concerned first-line treatment in patients with NSCLC and PD-L1 scores between 1 and 49%
This new product allows for subcutaneous dosing of daratumumab
Findings from 16 centres worldwide
FDA also approved a companion diagnostic for capmatinib
Balancing pandemic control with providing continued cancer care
It is indicated in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation
An FDA-approved companion diagnostic is not required to initiate treatment with niraparib for this indication
With Manuela Eicher, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.